DMAA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Drugs Made In America Acquisition Corp. Ordinary Shares · Financial Services · Shell Companies

Open interactive chart View report data
Latest close 10.71 USD
0.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 1.6% above the Trend Line and sits at 98.0% of its 52-week range. The latest completed week returned 0.1%, after a 0.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.

Setup score 67 out of 100
Latest Close 10.71 USD 31 Jul 2026
1W Return 0.1% latest completed week
4W Return 0.6% short-term follow-through
12W Return 1.0% quarterly tape
Trend Breadth 88.5% 46 of 52 weeks active
Volume Ratio 0.2x vs 13-week average
What is working
  • The trend backdrop is active with a 46-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.1% Latest completed week; four-week move 0.6%. Indicator stack 94/83 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 72.67% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 52 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 1.6% above the Trend Line and sits at 98.0% of its 52-week range. The latest completed week returned 0.1%, after a 0.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 1.0012-week average 1.00

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure1.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.6% over four weeks, 1.0% over 12 weeks, and 4.3% over one year. The current trend has remained active for 46 consecutive weeks.

Performance by holding period

1W0.1%
4W0.6%
12W1.0%
26W2.7%
52W4.3%
Active trend streak46 weeks
Active weeks in one year46
Trend breadth88.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.80Latest activity-pressure read.
Pressure change7.2%Four-week change in activity pressure.
Leadership-6.32Latest relative-leadership reading.
RS change44.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 70% Model confidence 66%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
39.1x
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-0.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-0.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
500.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 52 relevant articles.

4 positive · 45 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-0.1%Distance below the 52-week high.
13-week volatility0.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher20 of 263 weeks finished lower.
Best week+0.5%Week of 20 Mar.
Worst week-0.1%Week of 15 May.
Latest week+0.1%Week of 31 Jul.

Shape of recent returns

Strong gains0
Modest gains20
Flat weeks3
Modest losses3
Sharp losses0
Recent vol0.1%13-week weekly-return volatility.
Base vol0.1%52-week weekly-return volatility.
Up/down split36/10Count of positive and negative weeks in the 52-week window.
Average skew0.1% / -0.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape72/100

Trend, activity pressure, participation, and risk combine to a 72/100 tape read.

 Indicator analysis73/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 1.00; No reversal markers Next-Week ExpectancyPositive 72.67%

Next-week expectancy is positive with a 72.67% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 48; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 52 relevant articles.

Drugs Made In America Acquisition Corp. Revenue Breakdown – BOATS:DMAAU Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202610.71 USD0.1%10.54 USD10.34 USD1.80-6.3228.3KOn
24 Jul 202610.70 USD0.3%10.53 USD10.34 USD1.75-6.2279.5KOn
17 Jul 202610.67 USD0.1%10.52 USD10.33 USD1.71-8.25193.2KOn
10 Jul 202610.66 USD0.1%10.51 USD10.33 USD1.72-12.45471.9KOn
3 Jul 202610.65 USD0.1%10.50 USD10.32 USD1.68-11.33139.7KOn
26 Jun 202610.64 USD0.1%10.49 USD10.32 USD1.73-11.00309.4KOn
19 Jun 202610.63 USD0.1%10.48 USD10.31 USD1.81-15.4322.5KOn
12 Jun 202610.62 USD0.0%10.47 USD10.31 USD1.95-13.7885.4KOn
5 Jun 202610.61 USD0.0%10.46 USD10.31 USD2.05-12.30322.9KOn
29 May 202610.61 USD0.1%10.45 USD10.30 USD2.13-16.6410.0KOn
22 May 202610.60 USD0.1%10.44 USD10.30 USD2.16-14.80517.6KOn
15 May 202610.59 USD-0.1%10.43 USD10.29 USD2.24-14.381.0KOn
8 May 202610.60 USD0.3%10.42 USD10.29 USD2.35-14.9682.9KOn
1 May 202610.57 USD0.2%10.41 USD10.28 USD2.34-11.1117.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.